Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
McKinsey
Merck
Medtronic
Boehringer Ingelheim

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Filgrastim - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for filgrastim

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Early Phase 1
Rutgers, The State University of New JerseyEarly Phase 1
Eli Lilly and CompanyPhase 1

See all filgrastim clinical trials

Recent Litigation for filgrastim

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Village at Camp Bowie I, L.P.2010-08-02

See all filgrastim litigation

Company Disclosures: US Patents for filgrastim

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Kirin- Amgen Inc. (Thousand Oaks, CA) 2006-03-07 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2005-08-23 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-03 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-10 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Kirin- Amgen Inc. (Thousand Oaks, CA) 2006-03-07 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2005-08-23 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-03 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for filgrastim

These patents were identified by searching patent claims

Supplementary Protection Certificates for filgrastim

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14C/052 Belgium   Start Trial PRODUCT NAME: SILTUXIMAB; AUTHORISATION NUMBER AND DATE: EU/1/14/928/001 20140527
0106 Netherlands   Start Trial PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822
0100006 00032 Estonia   Start Trial PRODUCT NAME: REVOLADE-ELTROMBOPAG; REG NO/DATE: C(2010)1662 11.03.2010
14/048 Ireland   Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928/001-002 20140522
2003 Austria   Start Trial PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/227/001 20020822
5/2003 Austria   Start Trial PRODUCT NAME: PEGFILGRASTIM
2010007 Lithuania   Start Trial PRODUCT NAME: ELTROMBOPAGUM OLAMINUM; REGISTRATION NO/DATE: EU/1/10/612/001, 2010 03 11 EU/1/10/612/002, 2010 03 11 EU/1/10/612/003, 2010 03 11 EU/1/10/612/004, 2010 03 11 EU/1/10/612/005, 2010 03 11 EU/1/10/612/006 20100311
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Dow
AstraZeneca
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.